New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2013
06:05 EDTC, GSK, AAPL, CVS, MS, SNY, WMT, CS, BAOn the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: Fed Vice-Chairwoman Janet Yellen offered a vigorous defense of the central bank's easy-money policies, suggesting she favors continuing them amid a slow economic recovery and disappointing job market, the Wall Street Journal reports...Behind David Einhorn's protestations on Apple (AAPL) is a novel way to return cash to shareholders. Einhorn, of hedge fund Greenlight Capital, proposed that Apple issue a special class of stock, which he called "perpetual preferred," that would carry a high dividend yield. But with some investors feeling more confident about the future, shareholder pressure is growing to put that cash to work, the Wall Street Journal reports...REUTERS: The NTSB is investigating whether tiny fiber-like formations, known as dendrites, inside lithium-ion batteries could have played a role in battery failures on two Boeing (BA) 787 Dreamliners last month, Reuters reports...The shifting nature of Africa's disease burden is luring Big Pharma (SNY, GSK) as new opportunities open up for treating chronic diseases afflicting the middle classes, rather than just fire-fighting infection. European companies, in particular, hope to reap rewards by investing early in a region where many of them already have historic commercial ties, Reuters reports...BLOOMBERG: Global investment banks based in Europe and the U.S., facing regulatory and cost-cutting pressures at home, are losing market share (CS, MS, C) in emerging economies to smaller domestic competitors, Bloomberg reports...In 2007, Wal-Mart Stores (WMT) planned to open as many as 2,000 in-house medical clinics by mid-2012. Today they have fewer than 130 clinics and is closing locations faster than itís opening them. CVS Caremark (CVS) has about 630 MinuteClinics and aims to have 1,500 within four years, Bloomberg reports.
News For AAPL;BA;SNY;GSK;CS;MS;C;WMT;CVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | all recent news | >>
May 13, 2015
13:23 EDTWMTWal-Mart set to launch rival to Amazon Prime, The Information reports
Subscribe for More Information
13:15 EDTAAPLInquirer discusses recent Apple for BlackBerry takeover rumors
Subscribe for More Information
11:47 EDTCVSCVS Health says to pay $22M in settlement with DEA, USAO
CVS Health said in a regulatory filing that it has entered into an agreement with the U.S. Attorneyís Office for the Middle District of Florida and the U.S. Drug Enforcement Administration to resolve previously-disclosed allegations relating to the dispensing of certain controlled substances in Florida. CVS Health agreed to pay $22M and the settlement resolves all civil matters between the Company and the DEA in the state of Florida. This payment amount has been fully accrued for in prior fiscal periods.
11:38 EDTGSKGlaxoSmithKline downgraded to Neutral from Buy at UBS
Subscribe for More Information
11:18 EDTBASouthwest sees FY15 ASM growth approximately 7%; FY16 ASM growth 6%-7%
Subscribe for More Information
11:15 EDTBASouthwest sees FY15 CapEx approximately $1.8B
Subscribe for More Information
09:39 EDTAAPLActive equity options trading on open
Subscribe for More Information
09:32 EDTMSMorgan Stanley fined $2M by FINRA for short interest reporting, rule violations
FINRA announced that it has fined Morgan Stanley & Co. LLC $2M for short interest reporting and short sale rule violations that spanned a period of more than six years, and for failing to implement a supervisory system reasonably designed to detect and prevent such violations. FINRA found that Morgan Stanley, over several years, failed to completely and accurately report its short interest positions in certain securities involving billions of shares. FINRA also found that the firm's supervisory system was deficient because it failed to detect and prevent these violations over an extended period of time. FINRA found that over a seven-year period, Morgan Stanley included positions from the accounts of non-broker-dealer affiliates in a number of aggregation units when determining each unit's net position. FINRA also found that the firm's supervisory system was not reasonably designed to detect and prevent such violations. In concluding this settlement, Morgan Stanley neither admitted nor denied the charges, but consented to the entry of FINRA's findings.
08:59 EDTCEasterly Government Properties names Meghan Baivier as COO
Easterly Government Properties (DEA) announced that Meghan Baivier has been named EVP and COO, effective May 12. Baivier will be responsible for overseeing the alignment of the firmís growth strategy and financial goals with operations, capital markets and finance activities. Prior to joining Easterly Government Properties, Baivier served as VP of Citigroupís (C) Real Estate and Lodging Investment Banking group.
07:52 EDTAAPLApple Watch margins will grow to over 50%, says UBS
Subscribe for More Information
07:31 EDTSNYHeart Rhythm Society to hold a conference
Heart Rhythm 2015 is being held in Boston on May 13-16.
07:29 EDTCUBS to hold a conference
Subscribe for More Information
07:21 EDTCSCredit Suisse to hold a conference
4th Annual Disruptive Technology Conference is being held in San Francisco on May 13-14 with webcasted company presentations to begin on May 13 at 10:35 am; not all company presentations may be webcasted. Webcast Link
07:07 EDTGSKGSK, Emergent BioSolutions, Oxford initiate Prime Boost study of Ebola vaccine
A new phase 1 study has begun at the University of Oxford that will investigate the use of a modified vaccinia Ankara, or MVA, Ebola Zaire vaccine candidate, or MVA EBOZ, as a prime-boost to GlaxoSmithKline's (GSK) Chimp Adenovirus type 3, or ChAd3, Ebola vaccine candidate. The study, being conducted by the clinical research group of Professor Adrian Hill of the Jenner Institute, has received regulatory approval to begin from the United Kingdom's Medicines and Healthcare Products Regulatory Agency, or MHRA. The phase 1 study has a planned enrollment of 38 volunteers of which 6 will receive MVA EBOZ only while the other 32 will receive ChAd3-EBO-Z prime followed by MVA EBOZ boost. Emergent BioSolutions (EBS) manufactured the supply of MVA EBOZ to be used in this phase 1 study, which is being conducted in the U.K. with support from the Wellcome Trust and the U.K. Department for International Development.
07:06 EDTWMTAlibaba, Wal-Mart partner on consumer payments, China Daily reports
Alibaba (BABA) announced that it would partner with Wal-Mart (WMT) in China on consumer bill payments, according to China Daily. Under the deal, 25 Wal-Mart stores in the city of Shenzhen will enable consumers to pay their bills through Alibaba's payment service, and the arrangement will be gradually expanded to all of Wal-Mart's stores in China, the newspaper stated. Reference Link
07:05 EDTSNYSanofi exercises option on therapeutic program with Selecta Biosciences
Selecta Biosciences., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies, today announced that, under the terms of an existing strategic global collaboration, Sanofi has exercised its option to an exclusive license to develop an immunotherapy for the treatment of celiac disease. Under the terms of the collaboration, Selecta is eligible to receive research support and several pre-clinical, clinical, regulatory and sales milestones totaling up to $300 million for this new program in celiac disease. Additionally, Selecta is also entitled to up to double digit tiered royalties as percentage of product net sales for any commercialized immunotherapy resulting from these efforts with Sanofi. November 2012, Selecta announced that they had formed a strategic global collaboration to discover highly targeted, antigen-specific immunotherapies for life threatening allergies. Under the agreement, Sanofi obtained a first exclusive license to develop an immunotherapy designed to abate acute immune responses against a life threatening food allergen and an option to develop two additional candidate immunotherapies for allergies and celiac disease. With the exercise of this option by Sanofi, Selecta and Sanofi now have two initiatives actively advancing immune tolerance treatments under the terms of the 2012 agreement. In October 2014, Selecta and JDRF announced another collaboration with Sanofi to research novel antigen-specific immune therapies for Type 1 Diabetes.
07:03 EDTAAPLNext iPhone to feature 12 MP camera, be offered in rose gold, AppleInsider says
For its next iPhone 6 model, Apple will offer a new rose gold option, according to KGI Securities analyst Ming-Chi Kuo, who did not make clear whether the luxury model would be made of actual gold or if it will simply resemble the color of the high-end Apple Watch Edition, reported AppleInsider. Kuo also said Apple will upgrade the camera to 12 megapixels and suggested that some "Plus" models may use scratch-resistant sapphire covers, though that is dependent on success in testing, the report added. Reference Link
06:55 EDTAAPLInsiders speculate bidding war to erupt over AOL, Business Insider reports
The consensus speculation from investment bankers, hedge fund traders and people close to AOL (AOL) is that another company will emerge and offer a price for AOL that is higher than $50 per share, reports Business Insider. The potential suitors include Time Warner (TWX), Comcast (CMCSA), Yahoo (YHOO), Alibaba (BABA), Softbank (SFTBF), AT&T (T), Netflix (NFLX) and Apple (AAPL). Reference Link
06:11 EDTBABoeing ends work on only small satellite program, WSJ reports
Boeing is no longer working on a program for HySpecIQ, a private equity-backed startup, which had ordered two Boeing 502 Phoenix satellites that were expected to be launched in 2018, The Wall Street Journal reports. Boeing has ended work on the imaging spacecraft, its only small satellite order, due to the downturn in the natural resources market, the publication adds.
05:55 EDTAAPLTSMC awarded orders for SSD controller chips for Apple, DigiTimes reports
TSMC (TSM) has landed SSD controller chip orders from Apple, reports DigiTimes. According to industry sources, TSMC will utilize a 28nm process to fabricate controller cihps for Apple. Reference Link
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use